Pelthos Therapeutics Inc. · AMEX:PTHS
Pelthos Therapeutics — Chromocell Therapeutics — IPO Roadshow (October 2023)
23 slides from Pelthos Therapeutics's IPO roadshow presentation, Oct 16, 2023
Slide 1: Potential Breakthrough Drug for Erythromelalgia and Other Pain Indications
CHROMOCELL THERAPEUTICS CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Erythromelalgia and Other Pain Indications Issuer Free Writing Prospectus dated, October 16, 2023 Filed Pursuant to Rule 433 of the Securities Act 1933 , as amended Relating to Preliminary Prosp
Slide 2: Legal Disclaimer
CHROMOCELL THERAPEUTICS CORPORATION 2 Legal Disclaimer This presentation of Chromocell Therapeutics Corporation (“we”, “us”, “our” or the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as “a
Slide 3: Transaction Overview
CHROMOCELL THERAPEUTICS CORPORATION 3 Transaction Overview Offering Size: $8,000,000 New IPO Shares: 1,600,000 Expected Price Range: $4.50 - $5.50 Sole Bookrunner Titan Partners Group, a division of American Capital Partners Dose escalation study $2.0M Eye pain toxicology $0.5M Neuropathic pain stud
Slide 4: Capitalization Table
CHROMOCELL THERAPEUTICS CORPORATION 4 Capitalization Table Pre-IPO Cap Table (As converted, assumes $5.00 offering price and 2:1 reverse split) Common stock: 4,453,152 Automatic conversion of: Series A 599,314 April Bridge 103,183 September Bridge 52,833 Director Note 35,000 Investor Note 106,008 Se
Slide 5: Investment Highlights
CHROMOCELL THERAPEUTICS CORPORATION 5 Investment Highlights Overview Phase II life sciences company focused on developing patented non - opioid pain treatment compound (CC8464) through sodium channel blockade (NAV) Strategy Advance CC8464 towards commercialization, initially focusing on orphan desig
Slide 6: Pipeline
CHROMOCELL THERAPEUTICS CORPORATION 6 Pipeline Three active clinical / pre - clinical programs Asset Indication Preclinical Phase 1 Phase 2 Phase 3 Erythromelalgia Neuropathic Pain Eye Pain
Slide 7: Management Team
CHROMOCELL THERAPEUTICS CORPORATION 7 Management Team Frank Knuettel | Interim CEO & Chief Financial Officer Mr . Knuettel has 30 years of management experience in growing early - stage companies . He has raised more than $ 300 million via venture, public equity and debt offerings and managed more t
Slide 8: Development Plan - Erythromelalgia
CHROMOCELL THERAPEUTICS CORPORATION 8 CHROMOCELL THERAPEUTICS CORPORATION Development Plan - Erythromelalgia
Slide 9: Sodium channels are our bodies' electrical circuits
CHROMOCELL THERAPEUTICS CORPORATION 9 Sodium channels are our bodies “electrical circuits” Non - selective (e.g. carbamazepine) block all of the NaV channel subtypes
Slide 10: Why is NaV1.7 a Good Target for Pain Treatment?
CHROMOCELL THERAPEUTICS CORPORATION 10 Why is NaV1.7 a Good Target for Pain Treatment? Insensitivity to Pain Lack of NaV 1.7 (Rare condition initially described in family from Pakistan) Severe Pain Excessive NaV 1.7 activity (e.g. Erythromelalgia) Genetic validation suggests that suppressing NaV 1.7
Slide 11: CC8464 – Development Status
CHROMOCELL THERAPEUTICS CORPORATION 11 CC8464 – Development Status Preclinical • Potent ( nM ) inhibitor of human NaV1.7; Subtype selective • Demonstrated in vivo efficacy in several rodent models of pain: Acute, chronic neuropathic, inflammatory, visceral and post - surg ical • No CNS and muscle/mo
Slide 12: Erythromelalgia Clinical – Overview
CHROMOCELL THERAPEUTICS CORPORATION 12 Erythromelalgia Clinical – Overview Symptoms Erythema (heat), Pain (Usually severe burning pain but may include pins and needles or itching), Swelling, Change in perspira tio n and discoloration Types of EM Primary EM (Inherited or Sporadic SCN9A mutations + no
Slide 13: Phase Results / Dose-Escalation Study
CHROMOCELL THERAPEUTICS CORPORATION 13 Phase 1 Results / Dose - Escalation Study Phase 1 Results • No significant dose related trends or apparent differences compared to placebo in laboratory assessments, vital signs or ECG and no dose escalation stopping criteria were met • A moderate drug - induce
Slide 14: Phase 2a EM Proof of Concept Study (POC)
CHROMOCELL THERAPEUTICS CORPORATION 14 Phase 2a EM Proof of Concept Study (POC)* * The Company is planning to conduct a Phase 2 a study and the concept presented herein remains subject to change . A Randomized, Double - blind, crossover study of CC8464 and placebo in the treatment of Primary Inherit
Slide 15: Phase 2a POC Design and Endpoints
CHROMOCELL THERAPEUTICS CORPORATION 15 Phase 2a POC Design and Endpoints* Strategy and Endpoints Our strategy sets two key goals for the Phase 2a POC study with CC8464: • Obtain results validating CC8464 as a viable therapeutic for genetically - validated EM patients • Validate CC8464 and its blocka
Slide 16: Projected EM Development Plan
CHROMOCELL THERAPEUTICS CORPORATION 16 Projected EM Development Plan CC8464 has the potential for Breakthrough designation by the FDA, and if granted, could lead to completion of Phase II in 27 - 30 months and expectation of a 2027 NDA with post approval commitment NDA* Ph 1 DES Phase 2b/3 Post Appr
Slide 17: Erythromelalgia Competitive Environment
CHROMOCELL THERAPEUTICS CORPORATION 17 Erythromelalgia Competitive Environment (1) Company Phase of Development Mechanism of Action Note Phase II a NaV 1.7 Inhibition Small molecule / oral tablet Navega Therapeutics Pre - Clinical Zinc finger / CRISPR New technology & more challenging AlgotX Phase I
Slide 18: CC8464: Potential Additional Indications and Development Budget
CHROMOCELL THERAPEUTICS CORPORATION 18 CHROMOCELL THERAPEUTICS CORPORATION CC8464: Potential Additional Indications and Development Budget
Slide 19: CC-8464 for Ophthalmology
CHROMOCELL THERAPEUTICS CORPORATION 19 CC - 8464 for Ophthalmology Formulate Develop an ophthalmic formulation (eye drops) of CC - 8464 in Q4 2023 Potential Advantages: • Negates the risk of systemic hypersensitivity • Friendly Regulatory environment • High unmet medical need Evidence suggests that
Slide 20: CC-8464 for Neuropathic Pain
CHROMOCELL THERAPEUTICS CORPORATION 20 CC - 8464 for Neuropathic Pain Animal Models Animal models of neuropathic pain conducted by Chromocell suggest that CC - 8464 is likely to be effective in several types of Neuropathic Pain NaV1.7 has good potential for the treatment of Neuropathic Pain Tox Exis
Slide 21: Board of Directors & Scientific Advisory Board
CHROMOCELL THERAPEUTICS CORPORATION 21 CHROMOCELL THERAPEUTICS CORPORATION Board of Directors & Scientific Advisory Board
Slide 22: Independent Board of Directors
CHROMOCELL THERAPEUTICS CORPORATION 22 Independent Board of Directors Todd Davis | Chairman Mr . Davis is Chief Executive Officer and a member of the Board of Directors of Ligand Pharmaceuticals and has nearly 30 years of experience in biopharmaceutical and life sciences operations and investing . H
Slide 23: Scientific Advisory Board (SAB)
CHROMOCELL THERAPEUTICS CORPORATION 23 Scientific Advisory Board (“SAB”) Stephen G. Waxman | MD, PhD, Yale School of Medicine, Chairman • Bridget Marie Flaherty Professor of Neurology, Neuroscience, and Pharmacology • Chair, Department of Neurology ( 1986 - 2009 ), Yale University School of Medicine
Chromocell Therapeutics — IPO Roadshow (October 2023) on 6ix